Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)

Market Cap	2.78B -54.6%
Revenue (ttm)	710.14M -44.5%
Net Income	-340.68M
EPS	-0.85
Shares Out	400.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,784,211
Average Volume	2,952,233
Open	6.82
Previous Close	6.61
Day's Range	6.78 - 6.94
52-Week Range	6.03 - 10.37
Beta	0.46
RSI	56.67
Earnings Date	Apr 29, 2026

About SHA:605199

Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Haikou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 2,103
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605199

Financial Performance

In 2025, SHA:605199's revenue was 900.84 million, a decrease of -36.27% compared to the previous year's 1.41 billion. Losses were -287.37 million, 4.71% more than in 2024.